Breaking News

Eyevensys, a Biotechnology company raises $10M funding from Pontifax Venture Capital & existing investors

Eyevensys, a Biotechnology company raises $10M funding from Pontifax Venture Capital & existing investors

Eyevensys develops therapies for the treatment of ocular diseases by non viral gene therapy

Paris – Sept 15, 2016. RedNewswire/-

Eyevensys is a private biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease.

It uses two technologies, Electro-Transfection (Electro-Transfection of plasmids to the ciliary muscle) and Drug Device solution ( Electro-Transfection Injection System (ETIS)) for the treatment of eye diseases.

It has raised $10M in Series A funding round led by BpifrancePontifax Venture Capital and existing investors Boehringer Ingelheim Venture FundInserm Transfert Initiative  & CapDecisif.

The funds raised will be used to secure the clinical development of its products, pipeline includes EYS-606, a soluble TNFa receptor plasmid and EYS609, a device-plasmid combination method to express a anti-VEGF compound in-situ in the eye over extended periods of time. 

The company has partnered with Eurogentec, Fesys, CytoxLab, Axonal and others to develop its technology.

Featured image source

Facebook Auto Publish Powered By : XYZScripts.com